Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Wedbush sets higher price target on Ikena Oncology shares

EditorAhmed Abdulazez Abdulkadir
Published 2024-05-14, 09:40 a/m

On Tuesday, Ikena Oncology Inc. (NASDAQ:IKNA) received a positive assessment from a Wedbush analyst, who initiated coverage on the stock with an Outperform rating and set a price target of $8.00.

The company recently reported its first-quarter earnings for 2024, and the analyst noted that Ikena Oncology is making progress in its Phase 1 study of IK-930, which is targeting hippo mutated solid tumors. An update on this program is expected in the second half of 2024.

The analyst highlighted that Ikena Oncology has begun dosing patients with an optimized formulation of IK-930, aiming to achieve reduced variability in exposure and potentially enhanced activity compared to the original formulation. The company's current enrollment efforts are concentrated on mesothelioma patients.

Additionally, Ikena's MEK-RAF program is advancing with the dose-escalation of IK-595 in patients with RAS-altered solid tumors. Plans are in place to backfill select cohorts later in the year.

Preclinical data has indicated that IK-595 has potent antitumor activity across various xenograft models of cancers with different RAS/MAPK alterations. The compound also exhibits slower off-rate kinetics to MEK and durable inhibition of ERK phosphorylation compared to other RAF/MEK inhibitors.

Financially, Ikena Oncology concluded the quarter with a strong balance sheet, reporting $157.3 million in cash, cash equivalents, and marketable securities. The company believes these funds will be sufficient to support its operations into the second half of 2026.

Given the current trading price of the shares at below cash value, the analyst sees a favorable risk/reward balance for the stock and recommends buying shares ahead of the planned clinical update for IK-930.

InvestingPro Insights

As Ikena Oncology (NASDAQ:IKNA) navigates its clinical development milestones, real-time data from InvestingPro offers additional context for investors considering the company's financial health and market performance. The company's market capitalization stands at $63.7 million, indicating a relatively small size in the biotechnology market space. Despite the challenges highlighted by analysts, such as a significant sales decline of 41.35% over the last twelve months as of Q1 2023, Ikena Oncology holds more cash than debt, which could provide a cushion as it progresses through its clinical trials.

Investors should note that the company is quickly burning through cash, which is a critical factor to monitor considering the capital-intensive nature of drug development. Two InvestingPro Tips that may be particularly relevant for shareholders are that analysts have revised their earnings upwards for the upcoming period, suggesting a potential improvement in financial performance, and that the company’s liquid assets exceed its short-term obligations, indicating a degree of financial flexibility in the near term.

For those looking to delve deeper into Ikena’s financial metrics and analyst forecasts, InvestingPro provides a comprehensive suite of additional tips. Currently, there are 10 more InvestingPro Tips available for Ikena Oncology, which can be accessed by visiting Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, offering investors a more informed basis for their investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.